Response to mucosal antigen challenge in IgA nephropathy

Area of Science:

• Immunology
• Nephrology
• Gastroenterology

Background:

• IgA nephropathy (IgAN) is defined by IgA deposition in the glomerulus, but the IgA source remains unclear.
• Both mucosal and systemic immune systems are potentially involved in IgAN pathogenesis.
• Understanding the interplay between mucosal and systemic immunity is crucial for IgAN research.

Purpose of the Study:

• To investigate mucosal and systemic antibody production following mucosal antigen challenge in IgAN patients.
• To explore potential differences in immune cell responses between IgAN patients and healthy controls.

Main Methods:

• 9 IgAN patients and 11 controls received intranasal immunization with tetanus toxoid (TT).
• Serum and saliva antibody levels (IgG, IgA, IgA1, IgA2) were measured.
• In vitro IgA anti-TT production was assessed using Epstein-Barr virus-transformed peripheral blood lymphocytes.

Main Results:

• No significant differences in serum or saliva IgG, IgA, IgA1, or IgA2 antibody responses to TT were observed between groups.
• IgAN patients exhibited increased in vitro IgA anti-TT production from lymphocytes post-mucosal immunization.
• No enhanced antibody response or altered systemic response was found following mucosal immunization or priming.

Conclusions:

• Mucosal immunization does not appear to enhance systemic antibody responses in IgAN.
• Increased in vitro IgA production suggests altered immunocompetent cell traffic between mucosal and systemic compartments in IgAN.
• These findings may offer insights into the link between mucosal immunity and glomerular pathology in IgAN.